Compare PMCB & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PMCB | ICU |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 9.1M |
| IPO Year | N/A | N/A |
| Metric | PMCB | ICU |
|---|---|---|
| Price | $0.67 | $2.42 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 258.8K | 112.8K |
| Earning Date | 03-16-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $881,000.00 |
| Revenue This Year | N/A | $1,043.70 |
| Revenue Next Year | N/A | $54.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1195.59 |
| 52 Week Low | $0.63 | $2.20 |
| 52 Week High | $1.90 | $25.70 |
| Indicator | PMCB | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 37.27 | 56.17 |
| Support Level | $0.65 | $2.31 |
| Resistance Level | $0.81 | $2.74 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 7.09 | 21.57 |
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.